Yes, there is no clear data at this time that an AR/PARP inhibitor combination prolongs rPFS or OS in men with mCRPC who have progressed on a prior potent AR inhibitor, as largely these men were excluded or not included in PROpel, MAGNITUDE, or TALAPRO-2. For patients who develop mCRPC but have not ...

PARPi/ARSI combinations have consistently been shown to prolong progression free survival over ARSIs alone. (1, 2, 3) There are a number of combinations now available including olaparib/abiraterone, niraparib/abiraterone, talazoparib/enzalutamide. The overall survival data is immature in each of the...